Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) has announced an investor call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET. The call aims to discuss recent and upcoming developments within the company. Chairman and CEO Leonard Mazur will lead the discussion, joined by other members of the management team.

Investors can participate in the call via phone or webcast. The U.S. toll-free number is 1-888-243-4451, while the international number is 1-412-542-4135. A webcast option is also available, with registration required. A replay of the call will be accessible on the Citius website for 90 days following the event, providing an opportunity for those unable to attend live to catch up on the discussed developments.

Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET

CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments.

Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion.

Conference Call Details:

Date:	Tuesday, August 13, 2024
Time:	8:30 a.m. Eastern Time
Dial In:	1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international)
Webcast:	Register for the webcast here. A replay will be available on the Citius website (www.citiuspharma.com) for 90 days following the event.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:

STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-recent-and-upcoming-developments-302219218.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When is Citius Pharmaceuticals (CTXR) hosting its investor call?

Citius Pharmaceuticals (CTXR) is hosting its investor call on Tuesday, August 13, 2024, at 8:30 AM ET.

What will be discussed during the Citius Pharmaceuticals (CTXR) investor call?

The investor call will discuss recent and upcoming developments for Citius Pharmaceuticals (CTXR).

How can investors participate in the Citius Pharmaceuticals (CTXR) call on August 13, 2024?

Investors can participate by dialing 1-888-243-4451 (U.S. toll-free) or 1-412-542-4135 (international), or by registering for the webcast on the Citius website.

Will there be a replay available for the Citius Pharmaceuticals (CTXR) investor call?

Yes, a replay of the call will be available on the Citius Pharmaceuticals website (www.citiuspharma.com) for 90 days following the event.